KR20120092592A - 위장관 질환을 위한 오피오이드 수용체 길항제의 용도 - Google Patents

위장관 질환을 위한 오피오이드 수용체 길항제의 용도 Download PDF

Info

Publication number
KR20120092592A
KR20120092592A KR1020127008846A KR20127008846A KR20120092592A KR 20120092592 A KR20120092592 A KR 20120092592A KR 1020127008846 A KR1020127008846 A KR 1020127008846A KR 20127008846 A KR20127008846 A KR 20127008846A KR 20120092592 A KR20120092592 A KR 20120092592A
Authority
KR
South Korea
Prior art keywords
compound
opioid
effective amount
therapeutically effective
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127008846A
Other languages
English (en)
Korean (ko)
Inventor
리차드 엠 우드워드
Original Assignee
아돌로 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120092592(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아돌로 코포레이션 filed Critical 아돌로 코포레이션
Publication of KR20120092592A publication Critical patent/KR20120092592A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020127008846A 2009-09-18 2010-09-17 위장관 질환을 위한 오피오이드 수용체 길항제의 용도 Ceased KR20120092592A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
US61/243,616 2009-09-18

Publications (1)

Publication Number Publication Date
KR20120092592A true KR20120092592A (ko) 2012-08-21

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008846A Ceased KR20120092592A (ko) 2009-09-18 2010-09-17 위장관 질환을 위한 오피오이드 수용체 길항제의 용도

Country Status (19)

Country Link
US (1) US20110071163A1 (https=)
EP (1) EP2477627B1 (https=)
JP (1) JP5797655B2 (https=)
KR (1) KR20120092592A (https=)
CN (2) CN102695508A (https=)
AU (1) AU2010295464B2 (https=)
BR (1) BR112012006069A8 (https=)
CA (1) CA2774021A1 (https=)
CL (1) CL2012000676A1 (https=)
CO (1) CO6531453A2 (https=)
HK (1) HK1210959A1 (https=)
IL (1) IL218679A0 (https=)
MX (1) MX342548B (https=)
NZ (1) NZ598783A (https=)
PE (1) PE20120991A1 (https=)
RU (1) RU2561873C2 (https=)
TW (1) TW201118084A (https=)
WO (1) WO2011035142A1 (https=)
ZA (1) ZA201201954B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760880B1 (en) 2012-12-28 2015-07-08 Instytut Medycyny Doswiadczalnej I Klinicznej Peptidomimetics and their application
AR108535A1 (es) 2016-05-20 2018-08-29 Esteve Labor Dr Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法
CA3124115A1 (en) 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ES2188657T3 (es) 1994-04-22 2003-07-01 Yamanouchi Pharma Co Ltd Sistema para la liberacion especifica en el colon de un farmaco.
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
RU2695274C3 (ru) * 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
ES2226933T3 (es) * 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
ES2402749T3 (es) * 2007-12-11 2013-05-08 Theravance, Inc. Derivados de 3-carboxipropil-aminotetralina como antagonistas del receptor de opioide mu
TWI449685B (zh) * 2008-12-10 2014-08-21 Theravance Inc ３－羧基丙基－胺基四氫化萘化合物之結晶型
US9119848B2 (en) * 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose

Also Published As

Publication number Publication date
JP5797655B2 (ja) 2015-10-21
ZA201201954B (en) 2012-11-28
NZ598783A (en) 2013-07-26
BR112012006069A2 (pt) 2016-03-29
IL218679A0 (en) 2012-05-31
CO6531453A2 (es) 2012-09-28
RU2012115450A (ru) 2013-10-27
CL2012000676A1 (es) 2012-10-19
RU2561873C2 (ru) 2015-09-10
MX342548B (es) 2016-10-04
AU2010295464A1 (en) 2012-04-12
CA2774021A1 (en) 2011-03-24
CN104958298A (zh) 2015-10-07
TW201118084A (en) 2011-06-01
MX2012003310A (es) 2012-07-17
EP2477627A1 (en) 2012-07-25
CN102695508A (zh) 2012-09-26
EP2477627B1 (en) 2018-08-15
JP2013505260A (ja) 2013-02-14
HK1210959A1 (en) 2016-05-13
AU2010295464B2 (en) 2015-11-26
US20110071163A1 (en) 2011-03-24
BR112012006069A8 (pt) 2017-10-10
WO2011035142A1 (en) 2011-03-24
PE20120991A1 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
ES2303085T3 (es) Composiciones que afectan a la perdida de peso.
CA2723685C (en) Oral administration of peripherally-acting opioid antagonists
CN109562281B (zh) 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
WO2004054511A2 (en) Analgesic combination comprising nalbuphine
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
CN102711759B (zh) 胆道疾病的治疗或预防药
Lynch III et al. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model
KR20120092592A (ko) 위장관 질환을 위한 오피오이드 수용체 길항제의 용도
JP2014515405A (ja) オピオイド受容体アゴニストの逐次投与のための組成物
ES2307025T3 (es) Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor.
KR101285645B1 (ko) 진통제
JP2012500248A (ja) 不安障害の治療
TW201713362A (zh) 選擇性抑制腸羧酸酯酶2酵素活性的組成物及方法
WO2015191686A1 (en) Methods of administering methylnaltrexone
Vadivelu et al. Buprenorphine pharmacology and clinical applications
CN111511349A (zh) 包含伊立替康或其药剂学上可接受的盐的用于口服给药的药剂学组合物
US20250345324A1 (en) Combination formulations of naloxone and atipamezole
WO2023283062A1 (en) Low-dose naltrexol and uses thereof
HK40111880A (zh) 低剂量纳曲醇和其用途
JPWO2004078177A1 (ja) 薬物・物質依存治療薬
HK1163526B (en) A medicament for treating schizophrenia comprising cilostazol
HK1163526A1 (en) A medicament for treating schizophrenia comprising cilostazol

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120405

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150914

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160118

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160822

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170329

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160822

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I